C113P: Sotatercept Biosimilar, Anti-EDF Fusion Protein

Catalog No.: C113P | **Product Name:** Sotatercept Biosimilar, Anti-EDF Fusion Protein

The research grade Sotatercept biosimilar protein is for research use only (RUO). Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.

PRODUCT SPECIFICATIONS

Catalog No.	C113P
Product Name	Sotatercept Biosimilar, Anti-EDF Fusion Protein
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	EDF; Erythroid differentiation protein; Activin beta-A chain; INHBA; Inhibin beta A chain
Summary	Recombinant Activin Receptor Type IIA-Fc Fusion Protein.
Isotype / Construct	Fusion – [ACVR2A (activin A receptor type 2A, ActR-II, ActRIIA)]2 – IGHG1 Fc (Fragment constant).
Source/Host	The anti-EDF fusion protein sotatercept biosimilar was produced in mammalian cells.
Specificity/Sensitivity	The in vivo grade sotatercept biosimilar specifically binds to the EDF protein.
Applications	ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by sotatercept.
Form Of Protein	0.2 μM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin	< 1 EU per 1 mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	The Sotatercept Biosimilar, Anti-EDF Fusion Protein is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	The research grade Sotatercept biosimilar protein is for research use only (RUO). Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.

REFERENCES & BACKGROUND

What is sotatercept biosimilar research grade? Sotatercept is a first-in-class activin receptor type IIA-Fc (ActRIIA-Fc) fusion protein that acts as a ligand trap for members of the transforming growth factor-beta (TGF-β) superfamily, particularly activins and growth differentiation factors. By sequestering these ligands, sotatercept rebalances pro- and anti-proliferative signaling in the pulmonary vasculature. Sotatercept (trade name Winrevair) is approved for the treatment of pulmonary arterial hypertension (PAH) to increase exercise capacity, improve WHO functional class, and reduce the risk of clinical worsening. Sotatercept biosimilar uses the same protein sequences as the therapeutic fusion protein sotatercept.